PE74799A1 - Combinaciones antivirales - Google Patents

Combinaciones antivirales

Info

Publication number
PE74799A1
PE74799A1 PE1998000375A PE00037598A PE74799A1 PE 74799 A1 PE74799 A1 PE 74799A1 PE 1998000375 A PE1998000375 A PE 1998000375A PE 00037598 A PE00037598 A PE 00037598A PE 74799 A1 PE74799 A1 PE 74799A1
Authority
PE
Peru
Prior art keywords
reverse transcriptase
inhibitors
composition
hiv protease
inhibitor
Prior art date
Application number
PE1998000375A
Other languages
English (en)
Spanish (es)
Inventor
Clair Martha Heider St
David Walter Barry
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709945.1A external-priority patent/GB9709945D0/en
Priority claimed from GBGB9719883.2A external-priority patent/GB9719883D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE74799A1 publication Critical patent/PE74799A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PE1998000375A 1997-05-17 1998-05-14 Combinaciones antivirales PE74799A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
GBGB9719883.2A GB9719883D0 (en) 1997-09-19 1997-09-19 Antiviral combinations

Publications (1)

Publication Number Publication Date
PE74799A1 true PE74799A1 (es) 1999-08-13

Family

ID=26311543

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000375A PE74799A1 (es) 1997-05-17 1998-05-14 Combinaciones antivirales

Country Status (12)

Country Link
EP (1) EP0979082A1 (ja)
JP (1) JP2001525839A (ja)
AR (1) AR012702A1 (ja)
AU (1) AU7912398A (ja)
BR (1) BR9809127A (ja)
CA (1) CA2289655A1 (ja)
CO (1) CO4950569A1 (ja)
HR (1) HRP980264A2 (ja)
MA (1) MA26496A1 (ja)
NO (1) NO995620L (ja)
PE (1) PE74799A1 (ja)
WO (1) WO1998052570A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990030A2 (en) * 1998-02-17 1999-10-31 Michael B. Maurin Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
PE20000559A1 (es) * 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
WO2013111147A1 (en) * 2011-12-19 2013-08-01 Hetero Research Foundation Extended release compositions of nevirapine
WO2014133085A1 (ja) 2013-02-27 2014-09-04 国立大学法人京都大学 がんの予防または治療用医薬組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc

Also Published As

Publication number Publication date
CA2289655A1 (en) 1998-11-26
WO1998052570A1 (en) 1998-11-26
NO995620D0 (no) 1999-11-16
CO4950569A1 (es) 2000-09-01
HRP980264A2 (en) 1999-02-28
EP0979082A1 (en) 2000-02-16
JP2001525839A (ja) 2001-12-11
AR012702A1 (es) 2000-11-08
AU7912398A (en) 1998-12-11
NO995620L (no) 2000-01-14
MA26496A1 (fr) 2004-12-20
BR9809127A (pt) 2000-08-01

Similar Documents

Publication Publication Date Title
ES2174992T3 (es) Productos intermediarios para la obtencion de compuestos inhibidores de proteasas retrovirales.
MY142948A (en) Benzophenones as inhibitors of reverse transcriptase
MX9403380A (es) Inhibidores de proteasa de vih utiles para el tratamiento de sida.
DK0656888T3 (da) Sulfonylalkanoylaminohydroxyethylaminosulfonamider, anvendelige som retrovirale protease-inhibitorer
CL2004002061A1 (es) Compuestos derivados de heterociclos condensados que contienen nitrogeno; composicion farmaceutica; y su uso como agente antiviral, inhubidor de integrasa y como agente anti-vih.
ES2177868T3 (es) Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
DE69333378D1 (de) Pharmazeutische zusammensetzungen mit interleukin-1 inhibitoren
EP0656886A1 (en) N- (ALKANOYLAMINO-2-HYDROXYPROPYL) SULFONAMIDES CAN BE USED AS RETROVIRAL PROTEASE INHIBITORS.
NO20052159L (no) Substituert (tiazol-2-yl)-amid eller sulfonamid som glykokinase-aktivatorer nyttige ved behandling av type 2 diabetes.
ES2174921T3 (es) Inhibidores de la proteasa del vih.
AR009145A1 (es) Compuetos heterociclicos de guanidinilo utiles como agonistas de alfa-2 adrenoreceptores y composiciones farmaceuticas que los comprenden
PE74799A1 (es) Combinaciones antivirales
NO993670L (no) Quinoksalin i trippelkombinasjon med proteaseinhibitorer og reverse transkriptaseinhibitorer som medikamenter for behandling av AIDS
PA8461601A1 (es) Isoquinolinas
ES2103493T3 (es) Uso de parathormona, de sus fragmentos biologicamente activos y de peptidos relacionados para el tratamiento del embarazo.
ES2069536T3 (es) Analogos del activador del plasminogeno tisular que tienen dominios modificados del factor de crecimiento.
ES2164724T3 (es) Uso de una enzima para preparar un agente para el tratamiento y/o la profilaxis de la coccidiosis.
AR049560A2 (es) Formas cristalinas de (2s,3s,5s)-2-(2,6-dimetilfenoxiacetil) amin 3-hidroxi-5-(2-(1-tetrahidropirimid-2-onil)-3-metilbutanol)amin-1,6-difenilhexano (lopinavir)
DK0669803T3 (da) Anvendelse af amidoaminer i ophthalmologiske sammensætninger
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
UY26329A1 (es) Antagonistas de los receptores de vitronectina
IT1255668B (it) Agenti ausiliari per operazioni di tintura e loro impiego
ATE253938T1 (de) Pharmazeutische kombination von antiviralen wirkstoffen
PE20000020A1 (es) Composiciones para el tratamiento del sida e infeccion del vih
PE20001244A1 (es) Formulaciones antiparasitos que contienen doramectina

Legal Events

Date Code Title Description
FC Refusal